Who benefits if NHS drug prices soar? Donald Trump and big pharma. Just one more way he's menacing Britain | Polly Toynbee
US tariff threats and pricing demands are pushing UK pharmaceutical investment away, undermining British life sciences and straining NHS drug-price negotiations.
Wes Streeting's row with pharma firms grows as talks end on NHS drug pricing
Government and pharmaceutical companies remain deadlocked over VPAG NHS drug pricing, so the existing high clawback rate will continue, risking reduced UK medicine launches.